Home > Haematology > ASH 2021 > Immune Thrombocytopenia > Sustained remission after TPO-RA discontinuation in chronic ITP

Sustained remission after TPO-RA discontinuation in chronic ITP

Presented By
Prof. Matthieu Mahevas, HĂ´pital Henri-Mondor, France
Conference
ASH 2021
Trial
STOPAGO
High rates of sustained remission were achieved in patients with chronic primary immune thrombocytopenia (ITP) who discontinued thrombopoietin-receptor agonist (TPO-RA) therapy after achieving a complete response (CR). The results of the STOPAGO study support progressive dose reductions of TPO-RAs in patients who achieved a stable CR on this treatment [1]. A recent prospective study observed durable remissions in approximately 30% of the patients with ITP after TPO-RAs discontinuation [2]. However, the study population included patients with newly diagnosed ITP, in whom spontaneous remission may occur. Therefore, Prof. Matthieu Mahevas (HĂ´pital Henri-Mondor, France) and colleagues conducted the prospective, multicentre, interventional STOPAGO study (NCT03119974) to assess the proportion of patients with chronic or persistent ITP that display sustained remission aft...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on